(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...
The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...
(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...
Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...
Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...
The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...
A total of 25 patients who received ≥2 cycles of toripalimab combined with TIP chemotherapy were enrolled. The objective response rate was 84.0%, with 2 patients achieving complete response and 19 ...
This analysis included 58 patients treated with gemcitabine intravesical system monotherapy in the SunRISe-1 cohort who had ...
Pain and Health-Related Quality-of-Life Outcomes with Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer (ARANOTE): Secondary and Exploratory Analyses of a Multicentre, Randomised, ...
Low Frequency of Sexual Intercourse, Discrepancy Between Erectile Function Measures, and Sexual Satisfaction Among Japanese Men Aged 45-64 Years: A Nationwide Cross-Sectional Study. Elevated Prostate ...
Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 63-year-old man who was diagnosed with de novo metastatic prostate cancer. Maha Hussein discusses the topic of optimal ...
Spatial Architecture Contributes to Failure of Bulk Biomarker-Guided Neoadjuvant Immunotherapy Selection in Bladder Cancer: The DUTRENEO Study - Beyond the Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results